Yap-Campos K, Sánchez-Gálvez X, Rivero-López CA

Idioma: Español
Referencias bibliográficas: 25
Paginas: 136-139
Archivo PDF: 506.55 Kb.

RESUMEN

La diabetes mellitus tipo 2 (dm2) está considerada como una de las enfermedades que mayor morbimortalidad tendrá en los próximos años en todo el mundo. En la actualidad se han desarrollado nuevas líneas terapéuticas que permiten ejercer un mejor control sobre esta patología. En este artículo se analizan los inhibidores de la dipeptidil peptidasa 4 (dpp4) como un enfoque en el tratamiento de la dm.

REFERENCIAS (EN ESTE ARTÍCULO)

1. International Diabetes Federation. Diabetes Atlas [Internet]. [Citado 2017 abril] Disponible en: www.idf.org/diabetesatlas

2. International Diabetes Federation. The diabetics epidemic: facts [Internet]. 2011. Disponible en: www.worlddiabetesday.org/tiles/docs/ diabetes_facts.pdf

3. Encuesta Nacional de Salud y Nutrición 2012. 2ª ed. México: Instituto Nacional de Salud Pública; 2013.

4. International Diabetes Federation. Diabetes Atlas [Internet]. [Citado 2017 junio] Disponible en: www.idf.org/diabetesatlas

5. Merlin CT, et al. Systematic literature review of dpp4 inhibitors in patient with type 2 diabetes mellitus and renal impairment. Diabetes Ther. 2016;7:439-54.

6. Chalmers J, Cooper ME. ukpds and the legacy effect. N Engl J Med. 2008;359(15):1618-20.

7. Defronzo RA. From the triumvirate to the ominous octet. Diabetes. 2009;58(4):773-95.

8. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7-18.

9. Drucker DJ. Therapeutic potential of dipeptidyl peptidase iv inhibitors for the treatment of type 2 diabetes. Expert opin Invest Drugs. 2003;12(1):87-100.

10. Bailey CL. Renal glucose reabsorption inhibitors to treat diabetes. Trends in Pharmacological sciences. 2011;32(2).

11. Neumiller, Wood L, Campbell RK. Dipeptidyl peptidase-4-inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010;30:463-84.

12. ukpds 33 study group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes Prospective Diabetes Study (ukpds) Group. Lancet. 1998;352:837-53.

13. Saydah SH, et al. Poor control of risk factors for vascular disease among adults with previously diagnosed. Diabetes. jama. 2004;291(3):335-42.

14. Gooben K, Graber S. Longer term safety of dpp4 in patients with type e diabetes mellitus: systematic review and metaanalysis. Diabetes, obesity and metabolism. 2012;14:1061-72.

15. Harshal R, et al. Meta-analysis of effect of dipeptidyl peptidase-4inhibitors on cardiovascular riskl in type 2 diabetes mellitus. The American Journal of Cardiology [Internet]. Disponible en: www.ajconline.org/10.1016. amjcard.2012.04.06.

16. White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-35.

17. Schernthauer G. Diabetic nephropathy: new approaches for improving glycemic control and reducing risk. J Nephrol. 2013;26(6):975-85.

18. Karagiannis Thomas, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus en the clinical setting: systemic review and meta-analysis. bmj. 2012;344:e1369.

19. Study Caroline [Internet]. [Citado 2017 abril 5]. Disponible en: www.clinicaltrials.gov

20. Nikolaidis LA, Mankard S, Sokos GG. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfuntion after successful reperfusion. Circulation. 2004;109:962-5.

21. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc-diabetol. 2012;11:3.

22. Gallwitz B1, Rosenstock J, Emser A, von Eynatten M, Woerle HJ. Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c< 7% with no hypoglycaemia and no weight gain over 2 years. Int J ClinPract. 2013;67(4):317-21.

23. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptinmonotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes ObesMetab. 2011;13(3):258-67.

24. Rehman MB, et al. Efficacy and safety of dpp-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled ramdomizaed clinical trials. Diabetes and metabolism. 2017;431:48-58.

25. Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. idf [Internet]. 2012; [citado 2017 abril 5]. Disponible en: www.idf.org